Table 2.
Use of Antiparkinsonian Medications and Corresponding LEDD Before the Implementation of LCIG, CSAI or in Patients Continuing CU
| LCIG (N=50) | CSAI (N=19) | CU (N=54) | ||||
|---|---|---|---|---|---|---|
| N (%) | LEDD (mg) (Mean ± SD) (Range) | N (%) | LEDD (mg) (Mean ± SD) (Range) | N (%) | LEDD (mg) (Mean ± SD) (Range) | |
| Oral levodopa | 50 (94%) | 972.5 ± 417.9 (250–2350) | 19 (100%) | 1185 ± 686.3 (500–2500) | 54 (100%) | 732.6 ± 230.1 (200–1200) |
| Dopamine agonists | 33 (62%) | 274.6 ±123.9 (100–560) | 12 (63%) | 437.2 ± 596.5 (105–2000) | 36 (67%) | 211.6 ±81.0 (100–360) |
| COMT inhibitors | 23 (43%) | 322.6 ± 230.8 (100–1200) | 13 (68%) | 442.7± 403.1 (75–1400) | 20 (37%) | 548.7 ±414.0 (132–1400) |
| MAO inhibitors | 17 (32%) | 100.0±0.0 (100–100) | 3 (16%) | 100 ± 0 (100–100) | 19 (35%) | 237.5 ± 388.9 (100–1200) |
| Others* | 12 (23%) | 204.3 ±108.3 (100–360) | 1 (5%) | 200 (200–200) | 15 (28%) | 293.2 ±443.9 (100–1625) |
Note: *Others= amantadine, apomorphine pen (in LCIG), levodopa/carbidopa/entacapone association